Overview

Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients

Status:
Unknown status
Trial end date:
2016-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study evaluates generic emtricitabine(FTC) in Chinese naive children chronic hepatitis B patients. Single group of child patients were enrolled, which include HBeAg positive and negative Chronic hepatitis B(CHB)group.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Asian-Pacific Alliance of Liver Disease, Beijing
Collaborators:
Beijing Ditan Hospital
Hebei Medical University Pharmaceutical Factory
National Health and Family Planning Commission, P.R.China
Treatments:
Emtricitabine
Criteria
Inclusion Criteria:

- Children with body weight ≥ 33 kg and who can swallow entire emtricitabine
capsle(200mg)

- HBsAg positive for more than 6 months

- HBeAg positive patients: HBV DNA ≥ 5log10 copies/ml

- HBeAg positive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
biopsy Knodell HAI ≥ 4

- HBeAg negative patients: HBV DNA ≥ 4log10 copies/ml

- HBeAg positive patients: ALT≥2×ULN;or liver biopsy G≥2;or liver biopsy S ≥2;or liver
biopsy Knodell HAI ≥ 4

- Nucleoside/nucleotide naive patients

Exclusion Criteria:

- - Diagnosed HCC with AFP and ultrasound, CT or MRI

- Creatine >130μmol/L or Ccr < 70mL/min

- Hemoglobin <100g/L

- Neutrophils <1.5E+9/L

- PLT<80E+9/L

- Coinfected with HAV,HEV,HCV,HDV or HIV

- ANA > 1:100

- Uncontrolled cardiovascular diseases, kidney diseases,lung diseases, neurological
diseases, digestive diseases,metabolic disorders, immune-compromised diseases or
cancer

- Drug abuse or alcohol addiction

- Previous history of taking agents of lamivudine, adefovir, tenofovir entecavir or
telbivudine

- Long-term use of immunosuppressor or immunomodulator 6 months before enrollment to
this trial

- Underwent liver transplantation or liver transplantation in schedule

- Allergic to nucleoside or nucleotide analogues

- Pregnancy or in breastfeeding